Subcutaneous vs Intramuscular TRT: Route, Formulation and Evidence

Compare the evidence

Separate the route from the medicine and the device

SubQ and IM describe tissue location. Cypionate and enanthate describe testosterone esters. An autoinjector and a vial describe delivery systems. A study or clinic comparison may change more than one of these at once.

The XYOSTED label is specifically for its subcutaneous product. The Depo-Testosterone label, revised September 2025 identifies an intramuscular cypionate product. If a clinician proposes an off-label route for a different formulation, ask them to explain the evidence, product suitability and training. Do not infer a route change or dose conversion from an article about another product.

Interpretation limit: Treating every formulation with the same hormone name as interchangeable ignores the product-specific prescription and evidence.

What the 234-person comparison can tell us

Choi and colleagues compared intramuscular testosterone cypionate with a subcutaneous testosterone enanthate autoinjector in 234 men, assessing laboratory outcomes after 12 weeks. Both groups had increased trough testosterone; the subcutaneous group was associated with lower post-treatment hematocrit and estradiol.

The comparison is useful, but it changes ester and delivery system as well as route. It does not isolate injection depth as the cause of the findings, and short-term laboratory differences do not prove fewer long-term cardiovascular events or better symptoms for everyone. A claim that “SubQ always lowers estrogen” goes beyond what this design establishes.

Interpretation limit: Do not convert an association between two treatment packages into a guarantee about switching the same vial from one tissue route to another.

A route change does not remove the need for monitoring

The FDA's February 2025 label update added or reinforced blood-pressure warnings after class-wide assessment. Both routes deliver systemic testosterone, so the route label is not a substitute for a safety plan.

Ask which symptoms and results will be followed, how blood sampling relates to the prescribed regimen, and when the clinician will reassess benefit or adverse effects. If the reason for changing route is discomfort or a skin reaction, describe what happened rather than selecting a new technique from a forum. The prescriber should distinguish a local issue from an inadequate clinical response or another medical problem.

Interpretation limit: Changing formulation, route, frequency and testing time together can make results harder to interpret; a higher level is not automatically a better outcome.

Fertility and cost remain separate decisions

A different injection route does not establish preserved sperm production. The AUA/ASRM fertility guidance concerns exogenous testosterone, not only intramuscular injections. Use the fertility explainer if biological parenthood is part of your plans.

For costs, collect the exact product, supplies, appointment and testing charges rather than comparing a device price against an incomplete vial quote. The TRT cost calculator normalizes written quotes; the free decision report helps organize unresolved questions. An insurance or price difference does not establish that two products are clinically interchangeable.

Interpretation limit: Comfort, coverage and convenience can matter without proving better fertility or long-term safety.

Put the research to use

Prepare a product-specific question list before changing the route. Use the planner for the clinical conversation and the decision report for comparing written costs and care terms.

• Download the educational diagram as a PNG for sharing (source check: October 24, 2026)
• Prepare questions for your clinician
• Organize clinic costs and questions with the free TRT decision report
• Explore the TRT Clinic Decision Kit
• Compare written TRT quotes
• Understand why TRT can affect sperm production
• Sources checked October 24, 2026. This is an editorial evidence review, not an independent clinical review. Historical studies keep their original dates. Sources: XYOSTED FDA label, July 2025; Depo-Testosterone label, September 2025; Choi 2022; FDA February 2025 update; AUA/ASRM 2024.

Frequently asked questions

Is SubQ testosterone better than IM?

There is no universal winner. Both can deliver testosterone, but the exact product, regimen, individual response and clinical goals matter. Evidence comparing different products cannot isolate route alone.

Is subcutaneous testosterone FDA-approved?

XYOSTED is an FDA-approved subcutaneous testosterone enanthate product. That does not give every testosterone vial an approved subcutaneous route; check the exact label with the prescriber.

Can I inject my IM-labeled vial subcutaneously?

Do not change the prescribed route based on this comparison. Ask the clinician and pharmacist about the exact formulation, whether the proposed use is off-label, and appropriate training.

Does SubQ TRT avoid high hematocrit or estradiol?

No guarantee is supported. A comparative study reported lower associated levels for one subcutaneous enanthate product than intramuscular cypionate, but route, ester and delivery system differed.

Will changing injection route protect fertility?

Route alone does not establish fertility preservation. Discuss current or future fertility goals with the prescriber rather than assuming a change in injection depth removes testosterone's feedback effects.